Topline results are expected in the first quarter of 2025 The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In ...

SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of ...

Patients with unexplained or refractory chronic cough (URCC) experienced nearly double the rate of depressive symptoms compared with control individuals without chronic cough, along with a more than ...

Chronic cough, defined as a cough lasting at least 8 weeks, affects approximately 5% of the European population, particularly older adults and individuals with a history of smoking. In some cases, ...

WASHINGTON--(BUSINESS WIRE)--Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, presented positive results from a Phase 2 proof-of-concept study ...

Please provide your email address to receive an email when new articles are posted on . These results, published in JAMA in conjunction with a presentation at the European Respiratory Society ...

Chronic cough is undergoing a pivotal shift—from being viewed merely as a symptom to being recognized as a distinct disease entity. From December 4 to 6, 2025, the 5th International Cough Conference ...

On Monday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

Pharma giant GlaxoSmithKline on Tuesday announced a deal to buy Canadian biotech Bellus Health for $2 billion, betting big on the firm’s cough medicine as it moves to shore up its slender drug ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Between baseline and day 21, there was a –67% change in ...